Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18797392 | IONIZABLE CATIONIC LIPIDS | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18752372 | METHOD FOR SIMPLY CONSTRUCTING TWO-COMPONENT VIRAL VECTOR AND RELATED APPLICATIONS THEREOF | June 2024 | June 2025 | Allow | 11 | 1 | 1 | No | No |
| 18191718 | COMPOSITION TO INCREASE CELLULARLONGEVITY | March 2023 | March 2025 | Abandon | 23 | 3 | 1 | No | No |
| 17883973 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | August 2022 | April 2025 | Allow | 32 | 2 | 0 | No | No |
| 17813984 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | July 2022 | March 2025 | Allow | 32 | 1 | 0 | No | No |
| 17867128 | METHODS AND MEANS FOR INDUCING AN IMMUNE RESPONSE | July 2022 | February 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17859564 | THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS | July 2022 | September 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17859470 | DELIVERY OF GENE THERAPY TREATMENTS | July 2022 | March 2025 | Allow | 33 | 1 | 0 | No | No |
| 17845660 | ANELLOVIRUS COMPOSITIONS AND METHODS OF USE | June 2022 | February 2025 | Allow | 32 | 2 | 0 | No | No |
| 17721063 | OCULAR DELIVERY OF THERAPEUTIC AGENTS | April 2022 | September 2023 | Abandon | 17 | 1 | 1 | No | No |
| 17705803 | MESSENGER RNA VACCINES AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 1 | 0 | No | No |
| 17699035 | CORONAVIRUS VACCINE | March 2022 | September 2023 | Abandon | 18 | 2 | 0 | Yes | Yes |
| 17570962 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | January 2022 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17560197 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | December 2021 | June 2023 | Abandon | 17 | 2 | 0 | No | No |
| 17560195 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | December 2021 | December 2023 | Abandon | 24 | 2 | 0 | No | Yes |
| 17558555 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | December 2021 | April 2023 | Abandon | 16 | 2 | 0 | No | No |
| 17553603 | RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF | December 2021 | January 2025 | Allow | 37 | 1 | 0 | No | No |
| 17547498 | BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID | December 2021 | August 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17541018 | CD25 PRE-SELECTIVE COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USE | December 2021 | September 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17517967 | AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOOD | November 2021 | March 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17489652 | ANELLOVIRUS COMPOSITIONS AND METHODS OF USE | September 2021 | March 2022 | Allow | 6 | 1 | 0 | No | No |
| 17488608 | TRANSGENIC PIG ISLETS AND USES THEREOF FOR TREATING DIABETES | September 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17487562 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | September 2021 | July 2024 | Allow | 34 | 1 | 0 | No | No |
| 17438135 | OPTIMISED RAG1 DEFICIENT GENE THERAPY | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17426613 | TREATMENT OF AGING OR AGE-RELATED DISORDERS USING XBP1 | July 2021 | June 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17382757 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | July 2021 | February 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17376135 | PROGRAMMABLE, SELF-ASSEMBLING PATCHED NANOPARTICLES, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS | July 2021 | July 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17371386 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS | July 2021 | August 2024 | Allow | 38 | 2 | 1 | No | No |
| 17368947 | DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS | July 2021 | September 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17347498 | TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY | June 2021 | February 2023 | Allow | 20 | 2 | 1 | Yes | No |
| 17343071 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | June 2021 | July 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17339607 | TRANSPOSITION OF NUCLEIC ACIDS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM HELIOTHIS | June 2021 | May 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17321328 | METHOD OF PREPARING NUCLEASE-RESISTANT DNA-INORGANIC HYBRID NANOFLOWERS | May 2021 | February 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17294296 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SMOOTH MUSCLE DYSFUNCTION | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17244445 | METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS | April 2021 | May 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17219116 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | March 2021 | September 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17189120 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | March 2021 | September 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17174505 | NEOANTIGENS EXPRESSED IN OVARIAN CANCER AND THEIR USES | February 2021 | February 2024 | Allow | 36 | 1 | 1 | No | No |
| 17170785 | PEPTIDE/LIPID-ASSOCIATED NUCLEIC ACIDS (PLANA) FOR NUCLEIC ACID DELIVERY | February 2021 | November 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17165159 | COMPOSITIONS AND METHODS FOR INDUCING SCARRING BY PERI-TUMORAL CELLS | February 2021 | July 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17154309 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | January 2021 | October 2024 | Allow | 45 | 2 | 2 | No | No |
| 17142731 | LIPID NANOPARTICLE MRNA VACCINES | January 2021 | March 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17124462 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS | December 2020 | August 2024 | Abandon | 44 | 5 | 2 | Yes | No |
| 17083771 | PROCESS FOR THE PREPARATION OF ERYTHROCYTES LOADED WITH ONE OR MORE SUBSTANCES OF PHARMACEUTICAL INTEREST AND SO OBTAINED ERYTHROCYTES | October 2020 | January 2025 | Allow | 51 | 2 | 1 | No | Yes |
| 17050918 | HIGHLY KNOTTED MOLECULAR TOPOLOGIES FROM SINGLE-STRANDED NUCLEIC ACIDS | October 2020 | February 2025 | Allow | 52 | 2 | 1 | No | No |
| 17072611 | Membrane-Receiver Complex Therapeutics | October 2020 | July 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17067101 | METHOD OF TREATING IMMUNOTHERAPY NON-RESPONDERS WITH AN AUTOLOGOUS CELL THERAPY | October 2020 | January 2025 | Abandon | 51 | 2 | 1 | No | Yes |
| 17033166 | VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER | September 2020 | September 2024 | Allow | 47 | 4 | 0 | Yes | No |
| 17029436 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | September 2020 | January 2025 | Allow | 52 | 4 | 0 | No | No |
| 17021555 | NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION | September 2020 | November 2023 | Allow | 38 | 2 | 0 | No | No |
| 17017150 | COMPOSITIONS AND METHODS FOR TREATING MPSI | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17015995 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | September 2020 | May 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16979138 | METHODS AND COMPOSITIONS FOR USE OF TUMOR SELF-ANTIGENS IN ADOPTIVE IMMUNOTHERAPY | September 2020 | March 2025 | Allow | 54 | 3 | 1 | No | No |
| 16977385 | BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS | September 2020 | August 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16990356 | Compositions for In Vitro Amplification of Nucleic Acids | August 2020 | September 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16983121 | IONIZABLE CATIONIC LIPIDS | August 2020 | January 2024 | Allow | 42 | 2 | 0 | No | No |
| 16941148 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | July 2020 | July 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16938242 | METHODS FOR THE TREATMENT OF PROSTATE CANCER | July 2020 | September 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16914567 | Targeted intracellular delivery of antiviral agents | June 2020 | December 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16914422 | NANOPARTICLES INCLUDING A GLATIRAMOID USEFUL IN POLYNUCLEOTIDE DELIVERY | June 2020 | November 2022 | Abandon | 29 | 2 | 1 | Yes | No |
| 16904493 | METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIR | June 2020 | November 2024 | Abandon | 53 | 3 | 1 | Yes | No |
| 16954458 | RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF | June 2020 | September 2021 | Allow | 15 | 2 | 1 | No | No |
| 16770012 | MICRO- AND NANONEEDLES FOR PLANT AND OTHER CELL PENETRATION | June 2020 | May 2023 | Abandon | 36 | 2 | 2 | No | No |
| 16765632 | POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA | May 2020 | January 2025 | Allow | 56 | 3 | 1 | No | No |
| 16872679 | Optically Transparent Silk Hydrogels | May 2020 | March 2024 | Allow | 46 | 2 | 0 | No | Yes |
| 16864492 | Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier | May 2020 | April 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16758704 | METHOD FOR IMPROVING FETAL HEMOGLOBIN EXPRESSION | April 2020 | April 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16758824 | METHOD FOR INCREASING FETAL HEMOGLOBIN EXPRESSION LEVEL | April 2020 | April 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16850425 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | April 2020 | September 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16755193 | ESOPHAGEAL TISSUE AND/OR ORGANOID COMPOSITIONS AND METHODS OF MAKING SAME | April 2020 | January 2025 | Allow | 57 | 3 | 1 | No | No |
| 16846174 | IR700 Nanocompositions for Cardiac Therapies and Applications | April 2020 | December 2023 | Abandon | 45 | 3 | 0 | Yes | No |
| 16842707 | TRANSPOSITION OF NUCLEIC ACIDS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM HELIOTHIS | April 2020 | March 2021 | Allow | 11 | 1 | 1 | No | No |
| 16833405 | PREPARATION METHOD OF MESENCHYMAL STEM CELL-DERIVED EXOSOMES BASED ON DRUG PRETREATMENT | March 2020 | July 2021 | Abandon | 16 | 2 | 0 | No | No |
| 16821061 | MESENCHYMAL STEM CELL OVER-EXPRESSING CXCR5, PREPARATION METHOD AND USE THEREOF | March 2020 | January 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16806761 | MECP2E1 GENE | March 2020 | March 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16806828 | MECP2E1 GENE | March 2020 | April 2024 | Abandon | 50 | 0 | 1 | No | No |
| 16799052 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | February 2020 | September 2022 | Abandon | 30 | 2 | 1 | No | No |
| 16794918 | Tracking and Manipulating Cellular RNA via Nuclear Delivery of CRISPR/CAS9 | February 2020 | January 2023 | Allow | 35 | 1 | 1 | No | No |
| 16639740 | EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAME | February 2020 | June 2024 | Abandon | 52 | 3 | 1 | Yes | No |
| 16638162 | CHEMOTAXIS-POTENTIATING PEPTIDES AND USES THEREOF | February 2020 | April 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16785814 | TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY | February 2020 | June 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16637723 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF VIRUS | February 2020 | November 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16633552 | DIBLOCK COPOLYMER, A MANUFACTURING METHOD AND SUITED APPLICATIONS | January 2020 | April 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16632119 | COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR INFECTIOUS DISEASE | January 2020 | May 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16626053 | SINGLE KIDNEY CELL-DERIVED ORGANOIDS | December 2019 | August 2023 | Allow | 44 | 2 | 1 | No | No |
| 16715692 | Compositions and Methods for Cancer Immunotherapy | December 2019 | December 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16696960 | COMPOSITIONS AND METHODS FOR INDUCING SCARRING BY PERI-TUMORAL CELLS | November 2019 | January 2024 | Allow | 50 | 6 | 1 | Yes | No |
| 16687724 | BIODEGRADABLE POLYMERS, COMPLEXES THEREOF FOR GENE THERAPEUTICS AND DRUG DELIVERY, AND METHODS RELATED THERETO | November 2019 | June 2021 | Allow | 19 | 2 | 1 | No | Yes |
| 16685283 | RNA INTERFERENCE DELIVERY FORMULATION AND METHODS FOR MALIGNANT TUMORS | November 2019 | February 2023 | Allow | 39 | 4 | 0 | Yes | Yes |
| 16657666 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | October 2019 | July 2020 | Allow | 9 | 1 | 0 | No | No |
| 16606028 | COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE | October 2019 | November 2023 | Abandon | 49 | 3 | 1 | Yes | No |
| 16603152 | COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY | October 2019 | April 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16591211 | CD25 PRE-SELECTIVE COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USE | October 2019 | May 2022 | Abandon | 31 | 2 | 0 | No | No |
| 16500349 | POROUS NANOPARTICLE-SUPPORTED LIPID BILAYER DELIVERY OF TRANSCRIPTIONAL GENE MODULATORS | October 2019 | November 2023 | Abandon | 50 | 2 | 1 | No | No |
| 16588362 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | September 2019 | April 2022 | Allow | 30 | 1 | 0 | No | No |
| 16549840 | PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF | August 2019 | April 2023 | Abandon | 44 | 4 | 1 | No | No |
| 16544433 | TISSUE SCAFFOLDS | August 2019 | December 2022 | Abandon | 40 | 3 | 1 | No | No |
| 16474638 | POLYMER NANOPARTICLE COMPOSITION FOR PLASMID DNA DELIVERY, AND PREPARATION METHOD THEREFOR | June 2019 | September 2022 | Abandon | 39 | 2 | 0 | No | No |
| 16474353 | THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS | June 2019 | April 2022 | Allow | 33 | 5 | 1 | No | No |
| 16448589 | ANELLOVIRUS COMPOSITIONS AND METHODS OF USE | June 2019 | September 2021 | Allow | 27 | 4 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner POPA, ILEANA.
With a 28.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner POPA, ILEANA works in Art Unit 1633 and has examined 896 patent applications in our dataset. With an allowance rate of 19.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner POPA, ILEANA's allowance rate of 19.3% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by POPA, ILEANA receive 3.21 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by POPA, ILEANA is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.6% benefit to allowance rate for applications examined by POPA, ILEANA. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 5.0% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 13.8% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 39.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 48.3% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 45.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 80.9% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.0% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.